EBIO Eleven Biotherapeutics, Inc. gains 65% May 8, 2018

Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck. It is also developing systemically-administered TPTs, including VB6-845d for the treatment of multiple types of epithelial cell adhesion molecule positive solid tumors. The company was founded in 2008 and is based in Cambridge, Massachusetts.http://www.priceseries.com/trade/EBIO-Eleven-Biotherapeutics-Inc-stock-gains-65-percent-a-Trade-Record-by-priceSeries-2018041920180508.html